CVE:MPHMedicure Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medicure Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeC$0.94MA: C$1.05▼C$1.1452-Week Range N/AVolume100 shsAverage Volume11,903 shsMarket CapitalizationC$10.80 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Medicure. Previous Next 3.0 Community Rank Outperform VotesMedicure has received 111 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedicure has received 75 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedicure has received 59.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote “Outperform” if you believe MPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedicure does not currently pay a dividend.Dividend GrowthMedicure does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicure insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$17,600.00 in company stock and sold C$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicure is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicure is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:MPH Previous Symbol CUSIPN/A CIKN/A Webwww.medicure.com Phone+1-204-4877412Debt Debt-to-Equity Ratio3.85 Current Ratio2.57 Quick Ratio1.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$18.30 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.88 Book ValueC$2.50 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares10,662,000Market CapC$10.80 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable TSXV:MPH Rates by TradingView Receive MPH News and Ratings via Email Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter. Medicure (CVE:MPH) Frequently Asked Questions When is Medicure's next earnings date? Medicure is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Medicure. How were Medicure's earnings last quarter? Medicure Inc. (CVE:MPH) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm earned $3.01 million during the quarter. View Medicure's earnings history. Has Medicure been receiving favorable news coverage? News stories about MPH stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Medicure. Who are some of Medicure's key competitors? Some companies that are related to Medicure include Botanix Pharmaceuticals (BOT), Race Oncology (RAC), Rezolute (RZLT), Covalon Technologies (COV), ContraVir Pharmaceuticals (HEPA), Microbix Biosystems (MBX), Emerald Health Therapeutics (EMH), Oragenics (OGEN), Ixico (IXI), Proteomics Int Lab (PIQ), Pharmaust (PAA), Actinium Pharmaceuticals (ATNM), IntelGenx Technologies (IGX), Redx Pharma (REDX) and Kazia Therapeutics (KZA). View all competitors. What other stocks do shareholders of Medicure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicure investors own include Dollarama (DOL), Alimentation Couche-Tard (ATD.B), Canoe EIT Income Fund (EIT.UN), ProMetic Life Sciences (PLI), Hudbay Minerals (HBM), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Detour Gold (DGC), Sinovac Biotech (SVA) and Viking Therapeutics (VKTX). Who are Medicure's key executives? Medicure's management team includes the following people: Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)Mr. James F. Kinley, CFO & Sec. (Age 41) What is Medicure's stock symbol? Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH." How do I buy shares of Medicure? Shares of MPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. How big of a company is Medicure? Medicure has a market capitalization of C$0.00 and generates C$18.30 million in revenue each year. What is Medicure's official website? The official website for Medicure is www.medicure.com. How can I contact Medicure? Medicure's mailing address is 1250 Waverley St Suite 2, WINNIPEG, MB R3T 6C6, Canada. The company can be reached via phone at +1-204-4877412. This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
